email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
841 - 855
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal
$5.00
Available
Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug
$5.00
Available
Zenas Files China IND for mAb to Treat Thyroid Eye Disease
$5.00
Available
Hengrui Reports PD-1 Combo Therapy Effective in Global Trial for Liver Cancer
$5.00
Available
CARsgen Reports Positive Results for CAR T Therapy in Solid Tumor Cancers
$5.00
Available
Coherus Returns Rights for Avastin Biosimilar to Innovent
$5.00
Available
Zhimeng Bio Starts US Trials for Novel Epilepsy Therapy
$5.00
Available
Zhaoke Signs $130 Million Deal for Two Eyedrop Near-Vision Treatments
$5.00
Available
Ascletis Starts US Trial of PD-L1 as AIDS/HIV-1 Cure
$5.00
Available
SCG to Start China/Singapore Trials of Cell Therapy for Hepatocellular Carcinoma
$5.00
Available
Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin
$5.00
Available
InxMed Adds $15 Million B+ Funding for China/US Pivotal Trials of FAK Inhibitor
$5.00
Available
Elpiscience Cleared for US Trials of Bispecific Immunotherapy in Solid Tumors
$5.00
Available
Jemincare Out-Licenses Global Rights (ex-China) for Novel Pain Drug to Finland’s Orion
$5.00
Available
Newsoara Ok’d to Start China Phase III Trial of Bowel Function Drug
$5.00
Available